华兰生物
(002007)
| 流通市值：200.63亿 | | | 总市值：232.78亿 |
| 流通股本：15.74亿 | | | 总股本：18.26亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,566,637,468.5 | 762,111,441.69 | 4,595,017,702.01 | 3,378,886,377.05 |
| 营业收入 | 1,566,637,468.5 | 762,111,441.69 | 4,595,017,702.01 | 3,378,886,377.05 |
| 二、营业总成本 | 1,241,495,278.17 | 545,394,537.65 | 3,373,662,053.19 | 2,486,370,142.96 |
| 营业成本 | 842,897,521.86 | 379,626,095.69 | 1,951,537,637.59 | 1,429,887,222.67 |
| 税金及附加 | 25,410,424.14 | 12,962,278.49 | 41,463,397.65 | 29,569,149.05 |
| 销售费用 | 140,764,896.41 | 42,416,454.79 | 818,067,517.05 | 606,912,297.65 |
| 管理费用 | 110,166,342.43 | 51,856,532.47 | 224,672,887.88 | 186,141,562.82 |
| 研发费用 | 125,260,947.9 | 59,505,137.95 | 337,463,026.21 | 234,642,551.42 |
| 财务费用 | -3,004,854.57 | -971,961.74 | 457,586.81 | -782,640.65 |
| 其中:利息费用 | 191,035.56 | 95,517.78 | 10,242,183.52 | 6,387,108.39 |
| 其中:利息收入 | 3,404,198.19 | 1,173,740.52 | 10,091,199.6 | 7,372,471.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,582,063.21 | 4,066,763.04 | 15,171,586.8 | 17,337,962.29 |
| 加:投资收益 | 97,533,695.75 | 33,139,690.31 | 62,497,631.37 | 85,482,183.32 |
| 资产处置收益 | -696,138.29 | -321,301.63 | 2,891,234.85 | 500,095.9 |
| 资产减值损失(新) | 12,739,217.1 | 200,043.72 | -58,207,765.52 | 12,277,453.7 |
| 信用减值损失(新) | 39,344,416.07 | 41,591,811.05 | -34,060,814.15 | -12,607,418.2 |
| 其他收益 | 6,752,980.89 | 3,164,489.81 | 18,894,571.04 | 12,593,010.37 |
| 四、营业利润 | 491,398,425.06 | 298,558,400.34 | 1,228,542,093.21 | 1,008,099,521.47 |
| 加:营业外收入 | 618,479.87 | 495,491.44 | 463,766.9 | 423,838.59 |
| 减:营业外支出 | 18,017,175.67 | 9,553,514.42 | 55,657,495.8 | 36,109,120.64 |
| 五、利润总额 | 473,999,729.26 | 289,500,377.36 | 1,173,348,364.31 | 972,414,239.42 |
| 减:所得税费用 | 78,808,328.32 | 46,905,881.15 | 173,355,516.73 | 144,713,247.09 |
| 六、净利润 | 395,191,400.94 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 395,191,400.94 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 383,354,561.74 | 230,349,018.41 | 940,400,665.87 | 784,423,022.36 |
| 少数股东损益 | 11,836,839.2 | 12,245,477.8 | 59,592,181.71 | 43,277,969.97 |
| 扣除非经常损益后的净利润 | 341,952,686.02 | 226,806,935.99 | 936,794,228.45 | 742,438,601.83 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.13 | 0.52 | 0.43 |
| (二)稀释每股收益 | 0.21 | 0.13 | 0.52 | 0.43 |
| 九、综合收益总额 | 395,191,400.94 | 242,594,496.21 | 999,992,847.58 | 827,700,992.33 |
| 归属于母公司股东的综合收益总额 | 383,354,561.74 | 230,349,018.41 | 940,400,665.87 | 784,423,022.36 |
| 归属于少数股东的综合收益总额 | 11,836,839.2 | 12,245,477.8 | 59,592,181.71 | 43,277,969.97 |
| 公告日期 | 2026-08-29 | 2026-04-27 | 2026-03-28 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |